Thoracic endovascular stent graft repair for ascending aortic diseases

Gabriele Piffaretti, Viviana Grassi, Chiara Lomazzi, William T. Brinkman, Tulio P. Navarro, Michael P. Jenkins, Santi Trimarchi, Rodrigo C. Bernardes, Ricardo J. Procopio, Joel E. Schneider, Ali F. AbuRahma, John A. Kaufman, Benjamin J. Pearce

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: We describe the preliminary results of thoracic endovascular aortic repair (TEVAR) in a group of patients with ascending aortic disease from the Global Registry for Endovascular Aortic Treatment (GREAT). Methods: We identified TEVAR performed for diseases truly originating from the ascending aorta. Between July 2011 and May 2015, 5014 patients were enrolled; six (0.12%) were identified and included in the analysis. One further patient was withdrawn from the study due to lack of a signed consent form. Patients having a “zone 0” proximal landing zone reported for their TEVAR without the presence of an ascending aortic disease were not included. Reinterventions of previous open and endovascular repair were also excluded. Results: Three males and three females were treated. Mean age was 69 years ± 10 years (range, 58-83 years). Indication for TEVAR was atherosclerotic aneurysm (n = 4; ruptured, n = 1), complicated type A dissection (n = 1, rupture), and pseudoaneurysm (n = 1). Mean maximum aortic lesion diameter was 60 mm 14 (range, 39-77 mm). Urgent intervention was performed in three (50%) cases. Primary clinical success was 100%. There was no TEVAR-related in-hospital mortality. Open conversion was never required. Complication such as cerebrovascular accidents, valve impairment, or myocardial infarction did not occur. All patients were discharged home alive. No patient was lost at a median follow-up of 26 months (range, 16-72 months). During the follow-up, no patient died and ongoing primary clinical success was maintained in all patients. Reintervention was never required; endoleaks, migrations, fractures, or ruptures were not observed. Conclusions: Preliminary “real-world” experience of ascending TEVAR shows satisfactory outcomes at short-term follow-up. Although concerns remain for “off-label” use of standard devices, TEVAR-related complications were not observed. Longer follow-up data are expected to confirm durability of these results.

Original languageEnglish
JournalJournal of Vascular Surgery
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Aortic Diseases
Stents
Thorax
Transplants
Rupture
Consent Forms
Off-Label Use
Endoleak
False Aneurysm
Hospital Mortality
Aneurysm
Registries
Aorta
Dissection
Stroke
Myocardial Infarction
Equipment and Supplies

Keywords

  • Ascending aortic aneurysm
  • Ascending TEVAR
  • GREAT registry

ASJC Scopus subject areas

  • Surgery
  • Cardiology and Cardiovascular Medicine

Cite this

Piffaretti, G., Grassi, V., Lomazzi, C., Brinkman, W. T., Navarro, T. P., Jenkins, M. P., ... Pearce, B. J. (2019). Thoracic endovascular stent graft repair for ascending aortic diseases. Journal of Vascular Surgery. https://doi.org/10.1016/j.jvs.2019.01.075

Thoracic endovascular stent graft repair for ascending aortic diseases. / Piffaretti, Gabriele; Grassi, Viviana; Lomazzi, Chiara; Brinkman, William T.; Navarro, Tulio P.; Jenkins, Michael P.; Trimarchi, Santi; Bernardes, Rodrigo C.; Procopio, Ricardo J.; Schneider, Joel E.; AbuRahma, Ali F.; Kaufman, John A.; Pearce, Benjamin J.

In: Journal of Vascular Surgery, 01.01.2019.

Research output: Contribution to journalArticle

Piffaretti, G, Grassi, V, Lomazzi, C, Brinkman, WT, Navarro, TP, Jenkins, MP, Trimarchi, S, Bernardes, RC, Procopio, RJ, Schneider, JE, AbuRahma, AF, Kaufman, JA & Pearce, BJ 2019, 'Thoracic endovascular stent graft repair for ascending aortic diseases', Journal of Vascular Surgery. https://doi.org/10.1016/j.jvs.2019.01.075
Piffaretti G, Grassi V, Lomazzi C, Brinkman WT, Navarro TP, Jenkins MP et al. Thoracic endovascular stent graft repair for ascending aortic diseases. Journal of Vascular Surgery. 2019 Jan 1. https://doi.org/10.1016/j.jvs.2019.01.075
Piffaretti, Gabriele ; Grassi, Viviana ; Lomazzi, Chiara ; Brinkman, William T. ; Navarro, Tulio P. ; Jenkins, Michael P. ; Trimarchi, Santi ; Bernardes, Rodrigo C. ; Procopio, Ricardo J. ; Schneider, Joel E. ; AbuRahma, Ali F. ; Kaufman, John A. ; Pearce, Benjamin J. / Thoracic endovascular stent graft repair for ascending aortic diseases. In: Journal of Vascular Surgery. 2019.
@article{6d0b53f8e8fb43e6bf65a95e933269b0,
title = "Thoracic endovascular stent graft repair for ascending aortic diseases",
abstract = "Objectives: We describe the preliminary results of thoracic endovascular aortic repair (TEVAR) in a group of patients with ascending aortic disease from the Global Registry for Endovascular Aortic Treatment (GREAT). Methods: We identified TEVAR performed for diseases truly originating from the ascending aorta. Between July 2011 and May 2015, 5014 patients were enrolled; six (0.12{\%}) were identified and included in the analysis. One further patient was withdrawn from the study due to lack of a signed consent form. Patients having a “zone 0” proximal landing zone reported for their TEVAR without the presence of an ascending aortic disease were not included. Reinterventions of previous open and endovascular repair were also excluded. Results: Three males and three females were treated. Mean age was 69 years ± 10 years (range, 58-83 years). Indication for TEVAR was atherosclerotic aneurysm (n = 4; ruptured, n = 1), complicated type A dissection (n = 1, rupture), and pseudoaneurysm (n = 1). Mean maximum aortic lesion diameter was 60 mm 14 (range, 39-77 mm). Urgent intervention was performed in three (50{\%}) cases. Primary clinical success was 100{\%}. There was no TEVAR-related in-hospital mortality. Open conversion was never required. Complication such as cerebrovascular accidents, valve impairment, or myocardial infarction did not occur. All patients were discharged home alive. No patient was lost at a median follow-up of 26 months (range, 16-72 months). During the follow-up, no patient died and ongoing primary clinical success was maintained in all patients. Reintervention was never required; endoleaks, migrations, fractures, or ruptures were not observed. Conclusions: Preliminary “real-world” experience of ascending TEVAR shows satisfactory outcomes at short-term follow-up. Although concerns remain for “off-label” use of standard devices, TEVAR-related complications were not observed. Longer follow-up data are expected to confirm durability of these results.",
keywords = "Ascending aortic aneurysm, Ascending TEVAR, GREAT registry",
author = "Gabriele Piffaretti and Viviana Grassi and Chiara Lomazzi and Brinkman, {William T.} and Navarro, {Tulio P.} and Jenkins, {Michael P.} and Santi Trimarchi and Bernardes, {Rodrigo C.} and Procopio, {Ricardo J.} and Schneider, {Joel E.} and AbuRahma, {Ali F.} and Kaufman, {John A.} and Pearce, {Benjamin J.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jvs.2019.01.075",
language = "English",
journal = "Journal of Vascular Surgery",
issn = "0741-5214",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Thoracic endovascular stent graft repair for ascending aortic diseases

AU - Piffaretti, Gabriele

AU - Grassi, Viviana

AU - Lomazzi, Chiara

AU - Brinkman, William T.

AU - Navarro, Tulio P.

AU - Jenkins, Michael P.

AU - Trimarchi, Santi

AU - Bernardes, Rodrigo C.

AU - Procopio, Ricardo J.

AU - Schneider, Joel E.

AU - AbuRahma, Ali F.

AU - Kaufman, John A.

AU - Pearce, Benjamin J.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objectives: We describe the preliminary results of thoracic endovascular aortic repair (TEVAR) in a group of patients with ascending aortic disease from the Global Registry for Endovascular Aortic Treatment (GREAT). Methods: We identified TEVAR performed for diseases truly originating from the ascending aorta. Between July 2011 and May 2015, 5014 patients were enrolled; six (0.12%) were identified and included in the analysis. One further patient was withdrawn from the study due to lack of a signed consent form. Patients having a “zone 0” proximal landing zone reported for their TEVAR without the presence of an ascending aortic disease were not included. Reinterventions of previous open and endovascular repair were also excluded. Results: Three males and three females were treated. Mean age was 69 years ± 10 years (range, 58-83 years). Indication for TEVAR was atherosclerotic aneurysm (n = 4; ruptured, n = 1), complicated type A dissection (n = 1, rupture), and pseudoaneurysm (n = 1). Mean maximum aortic lesion diameter was 60 mm 14 (range, 39-77 mm). Urgent intervention was performed in three (50%) cases. Primary clinical success was 100%. There was no TEVAR-related in-hospital mortality. Open conversion was never required. Complication such as cerebrovascular accidents, valve impairment, or myocardial infarction did not occur. All patients were discharged home alive. No patient was lost at a median follow-up of 26 months (range, 16-72 months). During the follow-up, no patient died and ongoing primary clinical success was maintained in all patients. Reintervention was never required; endoleaks, migrations, fractures, or ruptures were not observed. Conclusions: Preliminary “real-world” experience of ascending TEVAR shows satisfactory outcomes at short-term follow-up. Although concerns remain for “off-label” use of standard devices, TEVAR-related complications were not observed. Longer follow-up data are expected to confirm durability of these results.

AB - Objectives: We describe the preliminary results of thoracic endovascular aortic repair (TEVAR) in a group of patients with ascending aortic disease from the Global Registry for Endovascular Aortic Treatment (GREAT). Methods: We identified TEVAR performed for diseases truly originating from the ascending aorta. Between July 2011 and May 2015, 5014 patients were enrolled; six (0.12%) were identified and included in the analysis. One further patient was withdrawn from the study due to lack of a signed consent form. Patients having a “zone 0” proximal landing zone reported for their TEVAR without the presence of an ascending aortic disease were not included. Reinterventions of previous open and endovascular repair were also excluded. Results: Three males and three females were treated. Mean age was 69 years ± 10 years (range, 58-83 years). Indication for TEVAR was atherosclerotic aneurysm (n = 4; ruptured, n = 1), complicated type A dissection (n = 1, rupture), and pseudoaneurysm (n = 1). Mean maximum aortic lesion diameter was 60 mm 14 (range, 39-77 mm). Urgent intervention was performed in three (50%) cases. Primary clinical success was 100%. There was no TEVAR-related in-hospital mortality. Open conversion was never required. Complication such as cerebrovascular accidents, valve impairment, or myocardial infarction did not occur. All patients were discharged home alive. No patient was lost at a median follow-up of 26 months (range, 16-72 months). During the follow-up, no patient died and ongoing primary clinical success was maintained in all patients. Reintervention was never required; endoleaks, migrations, fractures, or ruptures were not observed. Conclusions: Preliminary “real-world” experience of ascending TEVAR shows satisfactory outcomes at short-term follow-up. Although concerns remain for “off-label” use of standard devices, TEVAR-related complications were not observed. Longer follow-up data are expected to confirm durability of these results.

KW - Ascending aortic aneurysm

KW - Ascending TEVAR

KW - GREAT registry

UR - http://www.scopus.com/inward/record.url?scp=85065822046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065822046&partnerID=8YFLogxK

U2 - 10.1016/j.jvs.2019.01.075

DO - 10.1016/j.jvs.2019.01.075

M3 - Article

AN - SCOPUS:85065822046

JO - Journal of Vascular Surgery

JF - Journal of Vascular Surgery

SN - 0741-5214

ER -